Supriya Lifescience Stock Screener | Share Price & Fundamental Analysis
SUPRIYA
Pharmaceuticals
Screen Supriya Lifescience share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹750.80
▲
6.05 (0.81%)
Share Price BSE
₹750.30
▲
4.70 (0.63%)
Market Cap
₹5,984.30 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.58
EPS (TTM)
₹23.35
Dividend Yield
0.13%
Debt to Equity
0.01
52W High
₹802.65
52W Low
₹589.75
Operating Margin
36.00%
Profit Margin
25.10%
Revenue (TTM)
₹725.00
EBITDA
₹269.00
Net Income
₹182.00
Total Assets
₹1,112.00
Total Equity
₹997.00
Supriya Lifescience Share Price History - Stock Screener Chart
Screen SUPRIYA historical share price movements with interactive charts. Analyze price trends and patterns.
Supriya Lifescience Company Profile - Fundamental Screener
Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUPRIYA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE07RO01027
Supriya Lifescience Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,112 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 | 231 |
| Current Assets | 437 | 398 | 465 | 498 | 266 | 196 | 133 | 120 | 115 | 129 |
| Fixed Assets | 453 | 310 | 262 | 190 | 100 | 99 | 85 | 91 | 89 | 76 |
| Liabilities | ||||||||||
| Total Liabilities | 1,112 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 | 231 |
| Current Liabilities | 33 | 29 | 25 | 19 | 31 | 32 | 24 | 45 | 51 | 39 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 997 | 815 | 700 | 616 | 269 | 149 | 94 | 55 | 46 | 42 |
| Share Capital | 16 | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 981 | 799 | 683 | 600 | 254 | 134 | 79 | 40 | 31 | 26 |
Screen SUPRIYA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 725 | 706 | 581 | 470 | 538 | 396 | 323 | 286 | 222 | 191 | 172 | 140 |
| Expenses | 457 | 436 | 397 | 332 | 316 | 218 | 213 | 213 | 191 | 166 | 150 | 121 |
| EBITDA | 269 | 271 | 184 | 138 | 222 | 178 | 110 | 73 | 31 | 25 | 22 | 20 |
| Operating Profit % | 36.00% | 37.00% | 30.00% | 28.00% | 40.00% | 44.00% | 32.00% | 23.00% | 10.00% | 9.00% | 12.00% | 12.00% |
| Depreciation | 24 | 20 | 16 | 12 | 10 | 7 | 6 | 5 | 5 | 5 | 4 | 3 |
| Interest | 2 | 2 | 2 | 3 | 4 | 4 | 7 | 10 | 11 | 12 | 10 | 7 |
| Profit Before Tax | 242 | 249 | 166 | 124 | 207 | 167 | 96 | 57 | 15 | 8 | 8 | 10 |
| Tax | 52 | 61 | 47 | 34 | 55 | 44 | 23 | 18 | 6 | 2 | 2 | 2 |
| Net Profit | 182 | 188 | 119 | 90 | 152 | 124 | 73 | 39 | 9 | 6 | 6 | 8 |
| EPS | 22.70 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 10.02 | 5.39 | 1.19 | 3.87 | 3.89 | 16.82 |
Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals
Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 165 | 113 | 64 | 49 | 76 | 117 | 49 | 28 | 27 | 14 |
| Investing Activities | -152 | -174 | -124 | -60 | -47 | -25 | 5 | -5 | -27 | -33 |
| Financing Activities | -8 | -22 | -10 | 150 | -15 | -29 | -50 | -20 | -2 | 21 |
| Net Cash Flow | 4 | -83 | -70 | 139 | 15 | 62 | 4 | 3 | -2 | 2 |
Screen SUPRIYA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.28% |
| FII Holding | 7.19% | 6.78% | 5.46% | 5.36% | 4.95% | 6.03% | 6.52% | 0.00% |
| DII Holding | 4.26% | 4.86% | 5.22% | 5.30% | 5.48% | 5.45% | 4.92% | 7.65% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.40% | 16.39% | 16.77% | 17.06% | 17.19% | 0.00% | 16.28% | 15.54% |
| Other Holding | 3.85% | 3.67% | 4.25% | 3.98% | 4.08% | 20.23% | 3.98% | 8.53% |
| Shareholder Count | 91,051 | 91,928 | 87,912 | 87,980 | 89,621 | 85,328 | 89,394 | 95,605 |
Supriya Lifescience Dividend Screener - Share Yield Analysis
Screen SUPRIYA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.13% |
| 2024-March | ₹0.80 | 0.11% |
| 2023-March | ₹0.60 | 0.18% |
| 2022-March | ₹0.60 | 0.32% |
| 2021-March | ₹0.54 | 0.11% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Supriya Lifescience Index Membership - Market Screener Classification
Screen SUPRIYA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Supriya Lifescience Market Events Screener - Corporate Actions
Screen SUPRIYA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | -11.70% | ||
| Dividend | ₹ 0.60 /share | 13.53% | ||
| Dividend | ₹ 0.80 /share | 74.84% | ||
| Annual General Meeting | NA | -6.20% | ||
| Dividend | ₹ 0.60 /share | -0.06% | ||
| Annual General Meeting | NA | 11.37% | ||
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -6.66% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.96% |
| 2025-05-27 | 2025-05-27 | Quarterly Result Announcement | NA | 5.82% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 9.11% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -1.41% |
Supriya Lifescience Competitors Screener - Peer Comparison
Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,374 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 168,188 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 129,963 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,319 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,537 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,138 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,141 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,645 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 69,115 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,336 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Supriya Lifescience Company Announcements - News Screener
Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2026-01-03 | Closure of Trading Window | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-12 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On November 12 2025 | View |
| 2025-11-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-05 | Board Meeting Intimation for To Consider And Approve Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-24 | Voting Results For 17Th Annual General Meeting | View |
| 2025-09-24 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-24 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |